Colon Targeting News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Triastek announced they have completed its first human (FIH) study of its third 3D printing drug product, T21, designed to treat moderate to severe ulcerative colitis (UC).

United statesTim brownXiaoling liEli lillyDrug administrationMerck kgaaMerck kgaBoehringer ingelheimTriastek incColon targetingMelt extrusion depositionInvestigational new drugUnited states foodIrst human studyNih studyD printing drug product